Page 1

FOR IMMEDIATE RELEASE Exhibit 99.2 Therapeutics MD TherapeuticsMD Announces Third Quarter 2021 Financial Results Quarterly total net product revenue of $ 24.5 million , an increase of 41.1 % over Q3 2020 - - ANNOVERAⓇ TRX of 8,351 , an increase of 62.7 % over Q3 2020 - - Cost savings initiative to reduce SG & A by $ 40 million in 2022 ; anticipated additional savings of approximately $ 20 million annualized tied to the divestiture of vitaCare - - Hugh O'Dowd , President , to become Chief Executive Officer ; Robert Finizio appointed Vice Chair of the Board - - Conference call scheduled for 8:30 a.m. ET today - BOCA RATON , Fla . – November 11 , 2021 - TherapeuticsMD , Inc. ( “ TXMD ” or the “ Company ” " ) ( NASDAQ : TXMD ) , an innovative , leading women's healthcare company , today reported financial results for the third quarter ended September 30 , 2021. In addition , today the Company announced a significant cost savings initiative designed to reduce its annual costs in 2022 by at least $ 40 million . This figure does not include savings from , or the costs associated with , the divestiture of vitaCare , which are estimated at approximately $ 20 million annually . " We have made significant changes to our business strategy , which we believe will help us achieve our goal of EBITDA breakeven in the second half of 2022. Specifically , we put a cost savings plan in place and we have implemented a more concerted focus on healthcare professionals . These refinements are already yielding results , as evidenced by the steady progress made during the third quarter , notably the strong year - over - year growth in ANNOVERA prescriptions , said Hugh O'Dowd , President of TherapeuticsMD . " I would like to thank Rob for his leadership and vision in creating an innovative healthcare company with products that benefit women across their lifecycles . I would also like to formally welcome Mark Glickman as our Chief Commercial Officer . His commercial acumen is already having a positive impact on our day - to - day operations . Looking ahead , I am confident that we can reduce our annual expenses significantly , deliver value to shareholders , and most importantly , bring our high - quality products to the women who need them , " concluded O'Dowd . Third Quarter 2021 Financial Results and Business Highlights Net Product Revenue ( in thousands ) 2021 Three Months Ended September 30 , 2020 Product revenue : ANNOVERA IMVEXXY BIJUVA Prescription vitamin Product revenue , net License revenue Total revenue , net ANNOVERA ( segesterone acetate and ethinyl estradiol vaginal system ) $ 11,807 $ 8,016 3,298 1,348 24,469 937 25,406 $ 6,419 6,841 1,646 2,436 17,342 2,000 19,342 ANNOVERA net product revenue of $ 11.8 million for the third quarter of 2021 increased by $ 5.4 million compared to $ 6.4 million for the third quarter of 2020 . Approximately 8,350 ANNOVERA prescriptions were dispensed to patients during the third quarter of 2021. Prescriptions increased 62.7 % compared to the third quarter of 2020 . Over 4,500 health care providers ( HCPs ) prescribed ANNOVERA during the third quarter , of which nearly 29 % were new writers .